Stock viewCNBC-TV18
Gland Pharma shares jump 7% to 52-week high
Positive02 sources
GreyOak summary
Gland Pharma shares rose 7% after reporting a 58.2% year-on-year net profit increase to ₹291 crore in Q2FY27. Revenue grew 23.3% to ₹1,834 crore, driven by a 42% surge in US business. While Nomura maintains a 'Buy' rating citing re-rating potential, Citi retains a 'Sell' recommendation due to flat sequential performance.
What it affects
- Gland PharmaGLANDPositive 0
Shares jumped 7% on strong Q2 resultsRolling sentiment Positive +64
Source
Read the original at CNBC-TV18More Gland Pharma news
- Five Stocks To Buy Today, November 11: Gland Pharma, Sansera Engineering, Union Bank, And MoreNDTV Profit · Stock view ·
- Gland Pharma shares rally 8% to hit 4-year-high post strong Q2Moneycontrol · Results ·
- Pharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%Business Standard · Stock view ·
- Divis, Gland, Sai Life Sciences shares hit 52-week highsBusiness Today · Stock view ·
- Gland Pharma shares jump 4% as Q2 profit jumps 58%Economic Times · Results ·